Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMYTI3J)

Drug Name

R-56865 Drug Info

Synonyms

R-56865; UNII-8MUQ2U7UV6; 104606-13-5; R 56865; BRN 6616961; 8MUQ2U7UV6; CHEMBL137009; R56865; N-(1-(4-(4-Fluorophenoxy)butyl)-4-piperidinyl)-N-methyl-2-benzothiazolamine; 2-Benzothiazolamine, N-(1-(4-(4-fluorophenoxy)butyl)-4-piperidinyl)-N-methyl-; 2-Benzothiazolamine,N-[1-[4-(4-fluorophenoxy)butyl]-4-piperidinyl]-N-methyl-; ACMC-20m7dr; SCHEMBL933977; CTK4A3161; DTXSID40146613; AC1L3388; BDBM50067625; LS-40628; Benzothiazol-2-yl-{1-[4-(4-fluoro-phenoxy)-butyl]-piperidin-4-yl}-methyl-amine

Indication

Disease Entry	ICD 11	Status	REF
Angina pectoris	BA40	Terminated	[1]

Cross-matching ID

PubChem CID: 108043
CAS Number: CAS 104606-13-5
TTD Drug ID: DMYTI3J

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Voltage-gated calcium channel alpha Cav1.2 (CACNA1C)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
RAUWOLFIA SERPENTINA ROOT	DMWTVAN	Discovery agent	N.A.	Approved	[3]
ARC029	DMYNJHI	Alzheimer disease	8A20	Phase 3	[4]
SNAP-5089	DMROJEN	Heart arrhythmia	BC65	Terminated	[5]
NIGULDIPINE	DMSPWMF	N. A.	N. A.	Terminated	[3]
TH-9229	DMG1MPD	Reperfusion injury	ND56.Z	Terminated	[6]
CGS-27830	DM8TLY3	N. A.	N. A.	Terminated	[7]
PD-32577	DMBA15J	Discovery agent	N.A.	Investigative	[8]
CPU-228	DMM8FUT	Cardiac failure	BD10-BD13	Investigative	[9]
(-)-(S)-BayK8644	DMEA9KH	Discovery agent	N.A.	Investigative	[9]
CORYNANTHEINE	DM18CUZ	Discovery agent	N.A.	Investigative	[3]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Voltage-gated calcium channel alpha Cav1.2 (CACNA1C)	TTZIFHC	CAC1C_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000253)
2	Novel calcium antagonists with both calcium overload inhibition and antioxidant activity. 1. 2-(3, 5-di-tert-butyl-4-hydroxyphenyl)-3-(aminopropyl)... J Med Chem. 1998 Oct 22;41(22):4309-16.
3	Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716.
4	Dihydropyrimidines: novel calcium antagonists with potent and long-lasting vasodilative and antihypertensive activity. J Med Chem. 1989 Oct;32(10):2399-406.
5	Design and synthesis of novel dihydropyridine alpha-1a antagonists. Bioorg Med Chem Lett. 1999 Oct 4;9(19):2843-8.
6	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008159)
7	CGS 27830, a potent nonpeptide endothelin receptor antagonist, Bioorg. Med. Chem. Lett. 3(10):2099-2104 (1993).
8	Synthesis and biological activity of substituted bis-(4-hydroxyphenyl)methanes as N-type calcium channel blockers. Bioorg Med Chem Lett. 1999 Aug 16;9(16):2447-52.
9	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 529).